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ABSTRACT 
Background: Myositis is a group of rare autoimmune diseases. Muscle weakness and fatigue 
are the dominant symptoms and inflammation with T cells and macrophages is a 
characteristic finding in muscle tissue. Currently high-dose and long-term glucocorticoids is 
still the most important treatment but with limited efficacy and worrisome side effects. 
Therefore, investigations regarding inflammatory mediators and their roles in myositis 
pathogenesis are important in order to develop new therapies.  
Methods: In order to investigate the roles of different inflammatory mediators in patients with 
myositis, biological samples were investigated from clinically well-characterized patients in 
different phases of disease. Several techniques were employed: immunohistochemical 
staining on muscle tissue and cultured skeletal muscle cells; flow cytometry, ELISA and 
chemiluminescence immunoassay on blood samples. Hypotheses regarding molecular 
mechanisms for muscle weakness and fatigue were tested in animal models, where we mainly 
used enzymatically dissociated muscle fibers and mechanically dissected muscle fibers to 
measure the force and calcium release from the sarcoplasmic reticulum under various defined 
molecular conditions.   
Results: Based on previous observations on IL-1 expression in muscle tissue we first tested 
the role of IL-1 by using IL-1 blockade, anakinra, for 12 months in patients with refractory 
myositis. Eight of 15 patients had a clinical response which correlated to some response in 
biomarkers in blood, but muscle tissue inflammation persisted. Therefore, we searched for a 
new immune modulating target and found IL-15 to be expressed in muscle tissue of patients 
with myositis, and higher IL-15 expression was associated with more muscle dysfunction. 
Another approach was to test for the role of inflammatory molecules in early phases of 
muscle inflammation. In this context the extra nuclear presence of the alarmin high-mobility 
group box 1 (HMGB1) in the muscle fibers of patients with myositis without detectable 
inflammatory infiltrates is of interest. By in vitro experiments we showed that HMGB1 can 
influence muscle function by accelerating muscle fatigue and inducing MHC-class I 
expression via TLR4. Another receptor for HMGB1, TLR2, was also found in muscle tissue 
of patients with myositis and our animal study demonstrated that by knocking out TLR2 the 
skeletal muscle fibers became more muscle fatigue resistant.  
Conclusion: Collectively, the investigations in my thesis suggest that inflammatory 
mediators play important roles in the pathogenesis of myositis and different molecules may 
contribute in different phases of disease. Hereby, HMGB1 might induce muscle dysfunction 
at an early stage of the disease via TLR4 (or/and TLR2). IL-15 could be involved in 
developing muscle dysfunction via maintaining T cell homeostasis in the muscles. IL-1 may 
be important in a subset of patients by driving the adaptive immune system. However, more 
studies are needed for a comprehensive understanding of their roles in order to develop new 
therapies. 
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1. Idiopathic inflammatory myopathies  
Idiopathic inflammatory myopathies (IIMs), briefly called myositis ("myo" means muscle 
and "itis" means inflammation), is the term for a group of rare, heterogeneous inflammatory 
diseases mainly affecting skeletal muscles. The IIMs  are characterized clinically by muscle 
weakness and muscle fatigue, and histologically by the presence of inflammatory 
mononuclear cell infiltrates in muscle of the patients [1]. Glucocorticoids are the most 
commonly used medicine to treat patients with myositis, usually in combination with one or 
more immunosuppressive agents. Unfortunately, the beneficial effects are often limited and 
the adverse effects are prominent. These clinical observations indicate the need for 
development of new therapies. In recent years, a role of effector molecules/cytokines in the 
disease process has been suggested following the discovery of aberrant expression of some 
cytokines in muscle tissue of patients with myositis, such as tumor necrosis factor alpha 
(TNFα) and interleukin (IL)-1. However, anti-TNFα treatment in patients with myositis has 
been tried but the reports to date show inconsistent results [2-5], and thus, further 
investigations about other cytokines and their potential role in disease mechanism are 
needed [6-11].  
 
1.1. Classification 
Accurate classification of myositis is important in clinical studies to exclude involvement 
of misclassified patients with other myopathies and also sub-classification since different 
subgroups could have different response to conventional immunosuppressive treatment 
suggesting differences in underlying molecular mechanisms. Moreover, the clinical 
complications or prognosis could be different between subgroups. Currently, myositis is 
generally sub-classified into three main subgroups: polymyositis (PM), dermatomyositis 
(DM) and inclusion body myositis (IBM) based on patients’ clinical and histopathological 
features [12-15], and this is also the classification that has been used in this thesis.  
 
Since the 1980s, a variety of discoveries have begun to impact the sub-grouping of 
myositis; the myositis specific autoantibodies (MSA), further immunohistochemical 
characterization of muscle biopsies to include the presence of major histocompatibility 
complex (MHC)-class I expression in muscle fibers and subtyping of invading 
inflammatory cells [1, 16, 17]. Magnetic resonance imaging (MRI) has been used to 
visualize muscle inflammation and may also be helpful in the classification of myositis [18, 
19]. To solve the unmet need for an updated and validated set of classification criteria, an 
international, multidisciplinary data driven project is ongoing within the frame-work of the 
International Myositis Assessment and Clinical Trials (IMACS) but the final results are not 
available yet.  
 
1.2. Clinical manifestations and laboratory findings 
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The incidence of myositis is around 5-7/100,000 per year. Both polymyositis and 
dermatomyositis are more often seen in females than in males (2:1) [20]. Muscle weakness 
and muscle fatigue are the most commonly reported clinical symptoms both in polymyositis 
and dermatomyositis. Their muscle problems usually develop slowly over months and 
mainly affect proximal muscle groups and are often symmetric. Patients typically report 
difficulties with daily activities such as climbing stairs, getting up from a bench which often 
requires the use of proximal muscles, while fine motor movements that depend on distal 
muscle groups, such as writing, drawing or buttoning a shirt are rarely affected, especially 
at the early stage of polymyositis and dermatomyositis. Muscle tenderness and myalgia 
could occur in some patients, usually in the early stage of the disease course in patients with 
polymyositis and dermatomyositis [1, 21]. Aside from these common clinical features, each 
subgroup of disease also has some typical clinical symptoms and signs that are described in 
detail in the following subsections. 
 
1.2.1 Polymyositis 
Polymyositis usually has it onset at age 55-60 years old. It can occur alone or in association 
with other systemic autoimmune/connective tissue diseases in particular with systemic 
sclerosis and Sjögren´s syndrome. The most frequent complaint of the patients with 
polymyositis is the weakness in the shoulder and pelvic girdle muscles. Weakness of neck 
muscles especially the neck flexor occurs in about half of the patients, while ocular and 
facial muscles are rarely affected. Dysphagia may develop secondary to esophageal muscle 
dysfunction or circopharyngeal obstruction. While myalgia and joint pain are usual, severe 
tenderness and synovitis are uncommon. Pulmonary and cardiac manifestations can occur 
at any time during the disease course [1, 21]. 
 
1.2.2 Dermatomyositis 
The clinical features described above for polymyositis can be found in patients with 
dermatomyositis.  However, dermatomyositis is typically identified by characteristic skin 
rashes that can accompany, precede or follow the appearance of muscle weakness. The 
form of skin rash varies and can differ in different patients. It includes a heliotrope rash, 
blue-purple discoloration on the upper eyelids with edema, a flat red rash on the face and 
upper trunk, and erythema of the knuckles accompanied by a raised, violaceous scaly 
eruption (Gottron’s sign and Gottron´s papules). Differing from systemic lupus 
erythematosus (SLE) in which the phalanges are involved and the knuckles are spared, the 
erythema in dermatomyositis does not affect the phalanges. The erythematous rash can also 
appear on other parts of the body surfaces, including the knees, elbows, malleoli, neck and 
upper chest (V sign), or shoulders and back (shawl sign). The rashes can worsen after 
exposure to sunlight. The rashes may be very persistent but in some patients it also can be 
very faint and sometimes appear only transiently, in these cases, the diagnosis of 
dermatomyositis could be difficult. Dilated capillary loops at the base of fingernails are also 
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characteristic of dermatomyositis. The cuticles could be irregular, thickened, and distorted, 
and the lateral and palmar areas of the fingers may become rough and cracked with 
irregular, dirty horizontal lines (mechanic’s hands). Mechanic´s hands can also be seen in 
antisynthetase syndrome and is not specific for dermatomyositis.  
 
1.2.3 Inclusion body myositis 
A more accurate term is sporadic inclusion body myositis (sIBM). sIBM is often mis-
diagnosed as polymyositis or some other myopathy disease, and is commonly identified 
when a patient previously diagnosed as polymyositis does not respond positively to 
conventional immunosuppressive treatment.  
 
Sporadic inclusion body myositis is the most common acquired myopathy in patients above 
the age of 50 years old with the prevalence of 35/1,000,000 and a male-to-female ratio of 
3:1 [22]. It differs from polymyositis and dermatomyositis in that muscle weakness and 
muscle fatigue usually involve both the proximal leg muscles and distal muscles, especially 
foot extensors and finger flexors. These manifestations are often found in the early phase of 
disease and are valuable clues in the clinical diagnosis of the patients. A further important 
difference from polymyositis and dermatomyositis is that muscle atrophy is more 
frequently and earlier observed in the patients with sIBM than patients with other forms of 
myositis. The muscle weakness and muscle atrophy can be asymmetric, with the selective 
involvement of the quadriceps, iliopsoas, triceps, and biceps muscles. Patients often 
complain of their susceptibility to fall due to collapse of their knees because of the 
quadriceps’s weakness, or of difficulties in performing some fine motor movements, for 
example, holding a cup, turning a key or fastening a button owing to the weakness of their 
finger flexors. Head dropping is rarely observed. Sensory function such as touch is usually 
normal. The tendon reflexes could be normal especially at the early stages of the disease 
course, but can disappear in the late stages of the disease when the muscle atrophy becomes 
evident in the major muscle groups. The whole disease progression is usually quite slow 
and most patients with sIBM usually need some form of walking assistance after several 
years [7, 23].  
 
Laboratory tests are commonly used to help the diagnosis and assessment of myositis, 
especially the laboratory evaluation of muscle-derived factors that reflect muscle injury and 
the determination of serum autoantibodies. Measurement of serum enzymes released from 
muscle has been used for many years and is still the most widely used tests for muscle 
injury. Elevated serum levels of creatine kinase (s-CK) are often found in myositis patients 
but normal s-CK levels can be shown in patients especially in advanced cases in which 
there is already significant muscle atrophy [24, 25]. Other enzymes, such as lactate 
dehydrogenase (LD), asparate transaminase (AST) and alanine transaminase (ALT) could 
be also detected in elevated levels in the serum [25, 26].  
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Autoantibody, especially MSA testing is a useful tool in the diagnosis of myositis and more 
importantly some MSA are associated with a particular set of symptoms or organ 
involvements and can contribute to the treatment choice and the assessment of prognosis. 
The most frequent MSA is the anti-Jo-1 autoantibody, which is directed against histidyl-
tRNA synthetase and is present in 20-25% of patients with polymyositis or 
dermatomyositis. Their levels correlate with disease activity and they are usually associated 
with a distinct clinical phenotype, antisynthetase syndrome [27, 28]. Altogether, eight types 
of antisynthetase autoantibodies have been found [28-32] and MSAs can also direct against 
other autoantigens. This series has been reviewed in our recent publication [11].   
    
Muscle biopsy remains the gold standard for confirming the diagnosis of myositis [33]. The 
most typical changes in polymyositis are degeneration and regeneration of muscle fibers 
and CD8+ T cells invading non-necrotic fibers. In dermatomyositis, CD4+ T cells and B 
cells predominate in the perivascular areas and perifascicular atrophy [1, 21]. The typical 
features in sIBM are the “rimmed vacuoles” in the muscle fibers and Congo-red-positive 
amyloid deposits; otherwise it may appear identical to that of polymyositis. The “rimmed 
vacuoles” contain basophilic granular deposits and are easily demonstrated on cryostat 
sections stained with hematoxylin and eosin, while in paraffin sections they are difficult to 
observe owing to dissolution of the granular materials [1, 7]. However, despite the 
characteristic features described above, some patients may have a normal biopsy. 
 
1.3. Diagnostic criteria 
1.3.1. Diagnostic criteria for polymyositis and dermatomyositis 
Although there is currently no single universally accepted set of diagnostic criteria, there 
are some accepted principles as how to term or confirm the diagnosis of polymyositis and 
dermatomyositis. The most often used set was proposed by Bohan and Peter in 1975 [12]. 
The criteria they suggested are listed in Table 1.  
Table 1. Diagnostic criteria for polymyositis and dermatomyositis by Bohan and Peter in 
1975 
1. Symmetrical muscle weakness of limb-girdle and anterior neck flexors. 
2. Muscle biopsy revealing evidence of necrosis of type I and II fibers, phagocytosis, 
regeneration with basophilia, large vesicular sarcolemmal nuclei and prominent 
nucleoli, atrophy in a perifascicular distribution, variation in fiber size, and 
inflammatory exudates, often perivascular. 
3. Elevated serum levels of enzymes derived from skeletal muscle. 
4. Electromyography must show characteristics features. 
5. Characteristic cutaneous manifestation of dermatomyositis, including heliotrope 
rash or Gottron’s sign.  
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In addition the Bohan & Peter criteria require exclusion of several defined myopathies. The 
diagnosis of definite polymyositis is achieved when the first four criteria are met and there 
is no skin manifestation. The diagnosis of probable polymyositis is considered when three 
criteria are fulfilled without the rash. And a diagnosis of possible polymyositis is considered 
when two criteria are met without the skin rash.  
 
Similarly, definite dermatomyositis can be used when three or four of these criteria are 
fulfilled including the skin rash. Probable dermatomyositis can be diagnosed with two 
criteria (plus the rash), and when one criterion plus the rash is found, possible 
dermatomyositis can be used.  
 
1.3.2. Diagnostic criteria for sporadic inclusion body myositis 
Different diagnostic criteria for sIBM have been suggested by different groups worldwide. 
The most frequently used were proposed by Griggs and colleagues in 1995 [14]. The main 
criteria are listed in Table 2.  
 
Table 2. Diagnostic criteria for inclusion body myositis by Griggs and colleagues (1995) 
1. Duration of disease ≥ 6 months. 
2. Age at the onset of the disease ≥ 30 years old. 
3. Muscle weakness must affect proximal and distal muscles of arms and legs and 
patient must exhibit at least one of the following features:  
1). Finger flexor weakness. 
2). Wrist flexor weakness is more serious than wrist extensor weakness. 
3). Quadriceps muscle weakness. 
4. Serum creatine kinase < 12 times normal 
5. Muscle biopsy with the following features: 
1). Inflammatory myopathy characterized by mononuclear cell invasion of non-    
necrotic muscle fibers.  
2). Vacuolated muscle fibers. 
3). Intracellular amyloid deposits or tubulofilaments by electron microscopy. 
6. Electromyography must display consistent features of inflammatory myopathies.  
 
Definite inclusion body myositis can be diagnosed with the typical findings of muscle 
biopsy irrespective of other clinical features. In contrast, possible inclusion body myositis 
can be diagnosed by the presence of characteristic clinical and laboratory features but in the 
absence of the typical histological findings in the muscle biopsies from an individual.  
 
1.4. Treatment  
Due to the lack of a thorough understanding of disease mechanisms, there is no specific 
therapy for myositis patients so far. The main aims of the treatment are mainly to relieve 
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the symptoms, improve muscle function, slow disease progress, reduce or prevent more 
organ damage and provide necessary support so the patients can keep a relatively normal 
life as long as possible.  
 
Traditional pharmacological therapies are based on immunosuppression but are largely 
non-specific and run the risk of generalized immunosuppression. There are only a few 
controlled trials of treatment in polymyositis and dermatomyositis patients and therefore 
treatment recommendations are mainly based on clinical experience and open trials as 
summarized previously [8]. Introduction of glucocorticoids in the 1950s had a major impact 
with reduced morbidity and mortality and they are still the fundamental basis of treatment. 
High doses of glucocorticoids, 0.75-1 mg/kg/day, are often given for several weeks. Many 
patients respond with improved function, but few recover their former physical 
performance, and unwanted side effects are common. Therefore, many experts recommend 
a combination of glucocorticoids with another immunosuppressive drug to get a better 
response. The most commonly used first line agents are methotrexate 15-25 mg/week or 
azathioprine 2 mg/kg/day. If these are not tolerated or are without effect the next most 
recommended second line agents are: cyclosporine A which was found to be equally 
effective as methotrexate [34], or mycophenylate mofetile, as supported by case reports[35-
37].  One of the few placebo controlled trials that showed clear beneficial effects in 
treatment resistant dermatomyositis combined high dose intravenous immunoglobulin with 
conventional immunosuppressive agents for three months [38]. However, a more recent 
open study including treatment resistant DM, PM and IBM patients could not confirm this 
effect in any of the three myositis subsets; neither on clinical out-come measures nor on the 
inflammatory changes in muscle tissue [39]. In IBM the effects of pharmacological 
treatment were limited and to date there is few data as to the beneficial effects of 
immunosuppressive treatment in IBM. Thus, there is a clear need for new therapies for all 
forms of myositis and such development depends on improved knowledge on the key 
molecular pathways in these diseases. 
 
In recent years beneficial effects of increased physical exercise in addition to conventional 
immunosuppressive treatment have been demonstrated [40-42].  In a pilot study, a modest 
amount of resistant exercise led to improved clinical performance and in muscle tissue there 
was a reduced expression of genes involved in inflammation and fibrosis [43]. These 
findings indicate that exercise in established polymyositis or dermatomyositis may have a 
beneficial effect on molecular expression in the target organ of myositis. This needs to be 
replicated in larger studies.  
 
The new biological agents permit targeted therapy, and thereby they will be helpful in 
understanding key molecular pathways in diseases, as has been the case in the usage of 
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TNF blockade to treat rheumatoid arthritis (RA). However, the experience of treatment 
with targeting biological agents in myositis is still limited.  
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2. Disease mechanisms 
Immune mediated mechanisms are regarded to play important roles in the pathogenesis of 
myositis, which was supported by the observations of abundant expression of immune cells 
and effector molecules/cytokines in muscle tissue of patients with myositis [11]. T cells and 
macrophages are two major groups of immune cells that have been reported in muscle 
tissue of all subgroups of patients with myositis [44, 45]. Due to the prominent finding of 
both CD8+ T cells and CD4+ T cells a role of T cells in the disease mechanisms of myositis 
has been proposed [46-48]. T cells may have direct myotoxic effects targeting muscle fibers 
and leading to necrosis. Both T cells and macrophages may have indirect effect on muscle 
fibers through production of molecules such as cytokines which may affect the muscle fiber 
phenotype including the characteristic MHC-class I expression in muscle fibers of patients 
with myositis. In addition, both endothelial cells and muscle fibers may contribute to a 
proinflammatory environment by production of cytokines in muscle tissue of patients with 
myositis. This is particularly interesting in the context of cases where no inflammatory cells 
can be detected in a muscle biopsy. From clinical practice this is a well-known observation 
and can partly be explained by sampling error, but, in addition, there is no correlation 
between the degree of inflammatory infiltrates and muscle fiber necrosis and the degree of 
muscle weakness suggesting that other mechanisms than direct T cell mediated myo-
toxicity may contribute to muscle weakness and this could be by effects on muscle fiber 
contractility from molecules in the inflammatory environment in the muscle as supported 
from previous observations that TNF may affect muscle fiber contractility inducing muscle 
weakness [49]. Another interesting observation from longitudinal studies is the persistence 
of T cells in muscle tissue in patients with persisting muscle weakness despite conventional 
immunosuppressive treatment given for several months. This observation has been 
addressed in our research group and a striking predominance of a subphenotype of T cells 
of both CD4+ and CD8+ lineage of T cells, so called CD28
null
 T cells have been observed 
in muscle tissue and peripheral blood in patients with PM, DM and IBM. These cells have 
restricted T cell receptor patterns suggesting that they are antigen driven and are apoptosis 
resistant which may contribute to their persistence in muscle tissue despite treatment. All 
together previous studies suggest that both T cell mediated muscle weakness as well as 
other mechanisms may contribute to the clinical symptoms in these patients.     
 
TNF was the first cytokine to be targeted by treatment in patients with myositis due to the 
success of TNF-blockade in rheumatoid arthritis. However, the effects have been 
contradictory [2-5]. In one open study using infliximab treatment, some patients even flared 
and induction of type I interferon activity was recorded arguing against TNF as a key 
molecule in chronic resistant myositis [2]. Therefore the importance of TNF is still 
controversial in myositis.  
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Overexpression of IL-1α, IL-1β and their receptors was also demonstrated in muscle tissue 
from most patients with PM, DM and sIBM [50, 51]. Moreover, some benefinial effects of 
IL-1 blockade were reported in a case study of one myositis patient with anti-Jo-1 
autoantibodies [52]. These data suggest a role for IL-1 in the pathogenesis of myositis. 
Based on these observations we initiated an open label-mechanistic study with anakinra 
treatment in fifteen patients with refractory myositis (Paper I). The detailed results in this 
study are presented in the “Result and discussion” part of this thesis. One interesting 
finding was the persisting inflammation including T cells homeostasis in muscle tissue after 
treatment, even in the patients who had a good clinical response to anakinra. This 
persistence of T cells is consistent with our early observation that while macrophages 
decreased or even disappeared after glucocorticoids treatment, T cells in muscle tissue were 
usually maintained [53, 54]. As the most important T cell-growth factor, IL-2 is rarely found 
in muscle tissue of patients with myositis, it is possible that other cytokine (s) may have IL-2-
like functions stimulating T cell proliferation and differentiation. In this context we focused 
our interest on IL-15 (Paper II) as it shares some similar functions with IL-2 [55-59].  
 
To address the question on other molecular mechanisms that may have a role in causing 
muscle weakness than those that can be explained by T cells our research group had 
previously found that the alarmin high mobility group box protein (HMGB) 1 which is 
constitutively expressed in all nucleated cells was abnormally expressed in the cytosol of 
muscle fibers in patients with myositis. Moreover, based on animal studies it was 
demonstrated that HMGB1 can induce MHC-class I expression and accelerate muscle 
fatigue by reducing calcium release from sarcoplasmic reticulum [9, 10]. Therefore 
HMGB1 may be a molecule that can affect muscle fiber function and this could be 
independent of presence of T cells. However, the mechanisms how HMGB1 could possibly 
act on muscle fibers were not clear and needed to be investigated (Paper III). Toll-like 
receptors (TLRs) including TLR2, TLR4 and receptor for advanced glycated end products 
(RAGE) are known receptors for HMGB1 signaling. During our exploration about how 
HMGB1 mediates muscle dysfunction in paper III, we found some interesting muscle 
function modifications after the TLRs were knocked out, in which TLR2 knock-out mice 
raised our further interest that we wanted to explore to get a better understanding of muscle 
fiber fatigue (Paper IV).  
 
In the following parts the four inflammatory molecules (IL-1, IL-15, HMGB1 and TLR2) 
that were investigated in this thesis are introduced in more detail regarding their basic 
properties and potential roles in myositis.  
 
2.1. IL-1  
The IL-1 gene family includes three members: IL-1α, IL-1β, and IL-1 receptor antagonist 
(IL-1Ra) and two IL-1 receptors: IL-1RI and IL-1RII. The binding of IL-1α or IL-1β with 
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either receptor will initiate a signal transduction while IL-1Ra acts as a competitive 
inhibitor [60-62]. IL-1 is mainly produced by activated macrophages and by endothelial 
cells and may increase the expression of some pro-inflammatory genes [51, 63, 64]. One 
role relevant to disease is its ability to increase expression of adhesion molecules such as 
intracellular adhesion molecule (ICAM)-1 on mesenchymal cells and vascular cell adhesion 
molecule (VCAM)-1 on endothelial cells, both of which have been found to be increased in 
muscle tissue in patients with myositis [65-68]. IL-1α can also suppress myoblast 
proliferation and myoblast fusion, leading to poor muscle cell regeneration [69]. IL-1 
receptors are expressed on endothelial cells [70] and more recently were also demonstrated 
to be expressed and co-localized with its reciprocal ligands, IL-1α, IL-1β and IL1-Ra on 
muscle fiber membranes in PM and DM patients, lending further support for a role of IL-1 
in the pathogenesis of myositis [50].               
 
IL-1α and IL-1β have been found to be consistently expressed in muscle tissue of PM, DM 
and IBM patients [50, 51, 63, 64, 71-76]. Elevated levels of these cytokines have been 
found in muscle tissue of patients with impaired muscle performance, both in the early 
phase before treatment and in a chronic phase of disease with persisting muscle weakness, 
indicating that IL-1 could be a potential target of therapy in myositis [51, 63, 64]. Further 
support for a role of IL-1 in myositis are the elevated serum levels of IL-1Ra mRNA and 
protein in patients with active PM and DM compared with inactive PM and DM and normal 
controls [77]. Serum IL-1Ra levels have also been shown to be significantly higher in PM 
and DM compared to patients with spondylarthropathies and normal controls. IL-1Ra levels 
were particularly elevated in patients with active myositis and decreased in response to 
therapy [78]. Moreover, the IL-1Ra A1 allele in Caucasians and the A3 allele in African-
Americans was found to be a risk factor for juvenile myositis compared to normal race-
matched controls [79]. 
 
Anakinra, a recombinant IL-1Ra, was recognized as the most effective current therapy for 
hereditary autoinflammatory syndromes related to mutations in the inflammasome 
component cryopyrin/NALP3 [80-82]. It has also shown promising results in the treatment 
of systemic-onset Still’s disease [83, 84]. In case of myositis there is very limited 
information. A case-report showed a rapid reduction of fever, polyarthritis and acute phase 
reactants following administration of anakinra in a patient with antisynthetase syndrome 
[85]. However, in a second case report on lupus myositis, there was no obvious effect of 
anakinra treatment [86]. Until recently there were no reports based on a larger group of 
patients with myositis. Therefore, we investigated the effects of anakinra in myositis 
patents in a pilot study of fifteen patients with refractory PM, DM and IBM. 
 
2.2. IL-15 
IL-15 belongs to the 4α-helix bundle cytokine family with some structural homology to IL-
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2. IL-15 meditates its functions via its receptor that consist of three components, IL-2Rβ, 
common gamma chain (γc) and IL-15Rα. IL-15Rα has a very high affinity for IL-15 [55-
59]. Traditionally it has been thought that IL-15 functions like other classic interleukin 
cytokines, such as IL-1, which can bind to its receptors and initiate downstream functions. 
But recent studies show that the way that IL-15 acts is quite different from others. It goes 
by the way called trans-presentation, which means that IL-15Rα-producing cells bind IL-15 
and then present it to cells expressing IL-2Rβ and γc subunits [57, 87, 88].   
 
Originally IL-15 was described as a T-cell-growth factor that promotes the proliferation of 
T cells in a fashion akin to that of exogenous IL-2 [58]. Stimulation of T cell receptor 
(TCR) with IL-15 has been shown to induce various activation antigens, such as CD69 
[89]. IL-15 was shown to protect concanavalin A-activated human T lymphoblasts from 
undergoing apoptosis after Fas or CD3 cross-linking or treatment with dexamethasone in 
vitro and in vivo [90]. Later additional roles of IL-15 during development of a variety of 
cells were also revealed, such as natural killer (NK) cells, NKT cells, and intestinal 
intraepithelial lymphocytes [91].  
 
IL-15 knock-out mice showed a lack of NK cells, deficiency in NKT cells (thymic and 
peripheral), deficiency in memory CD8+ T cells, decreased intestinal intraepithelial 
lymphocytes (i-IEL) TCRγδ cells and i-IEL CD8α cells [92]. IL-15Rα knock-out mice 
showed absence of NK cells, deficiency of NKT cells (30% of wildtype (WT)), deficiency 
of single-positive CD8+ T cells (thymus), deficiency of CD8+ T cells (periphery), and 
deficiency of memory CD8+ T cells [93].    
 
Both IL-15 and IL-15Rα have a widespread expression at the transcriptional level in a 
variety of normal human tissues and cells including skeletal muscle [57]. But due to strict 
posttranscriptional regulations, IL-15 and IL-15Rα are rarely detected at the protein level in 
normal tissues or organs [88]. However, several groups have reported the expression of IL-
15 in various tissues of patients with infectious diseases, cancer, autoimmune or 
inflammatory disorders such as RA where IL-15 protein was demonstrated in synovial 
fluids and synovial membranes [87, 94].  Agostini et al suggested a potential role for IL-15 
in the pathogenesis of pulmonary sarcoidosis as alveolar macrophages isolated from 
patients with active sarcoidosis expressed IL-15 mRNA and cytoplasmic or membrane IL-
15 protein, whereas macrophages isolated from patients with inactive disease or normal 
donors did not. In addition, CD4+ T cells isolated from bronchoalveolar lavage of patients 
with active sarcoidosis expressed components of the IL-2/15R complexes and proliferated 
in response to IL-15, suggesting that macrophages may provide a proliferative signal to T 
cells in the lungs during this disease process [95]. Patients with multiple sclerosis were 
found to have higher numbers of IL-15 mRNA-expressing blood mononuclear cells 
compared with patients with aseptic meningoencephalitis or healthy controls. Increased 
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numbers of IL-15 mRNA-expressing cells were found in the central nervous system 
compared to the blood of multiple sclerosis patients [96]. In addition, patients with chronic, 
progressive multiple sclerosis had higher IL-15 expression than those with relapsing, 
remitting multiple sclerosis. Later study confirmed this finding and also correlated it with 
the duration and durability of multiple sclerosis [97].   
 
A potential role of IL-15 in myositis is firstly highlighted by the finding of overexpression 
of IL-15 at the protein level in the muscle tissue of patients with PM and DM. One report 
based on three PM and two DM patients showed that IL-15 was predominantly expressed in 
muscle fibers and IL-15 was also expressed in myoblasts derived from muscle biopsies 
from these patients [98, 99]. High serum levels of IL-15 in PM and DM patients have also 
been reported [100]. All these observations suggest a potential role of IL-15 in PM and DM. 
Furthermore, as we mentioned earlier, T cells in muscle tissue of patients with myositis 
keep homeostasis even after glucocorticoid or anakinra treatment [53], while the most 
important T cell-growth factor, IL-2, is absent. Therefore, it is interesting to detect whether 
IL-15 can promote the proliferation of T cells in a fashion akin to that of exogenous IL-2 in 
myositis. 
 
2.3. HMGB1   
HMGB 1 is a ubiquitous non-histone protein present in the nucleus of cells. Inside the 
nucleus HMGB1 binds DNA and helps to regulate transcription and chromatin structure. 
However, when the cells are activated or die, HMGB1 can translocate from the nucleus to 
the cytosol and may be released out of the cell. Extracellular HMGB1 has been described to 
mediate different functions including chemotaxis, cytokine induction, and tissue damage or 
healing [101-103]. HMGB1 does not act via one unique receptor but rather uses receptors 
that are known to also bind other ligands. To date the most investigated are RAGE, TLR2 
and TLR4 [104, 105]. Recent studies also show that not only its cellular or extracellular 
location but also the redox statuses of three critical cysteines at positions 23, 45 and 106 
determine the biological activities of HMGB1. When all three cysteines are fully reduced, 
HMGB1 mediates chemotactic activity by forming a heterocomplex with CXCL12 and 
signals via CXCR4 in a synergistic fashion compared to CXCL12 alone. However, this 
HMGB1 isoform does not activate cells to produce cytokines. Disulfide HMGB1 (a 
disulfide bond formed between C23 and C45) will induce proinflammatory cytokine release 
via the TLR4 receptor signaling pathway. However, further oxidation of any of the cysteine 
residues will eliminate all proinflammatory activities [106, 107]. In addition, HMGB1 can 
promote inflammation by forming immunostimulatory complexes with other molecules 
including IL-1, endotoxin and DNA and additional molecules [108-113]. HMGB1 with its 
partner molecules can act synergistically via the receptors of the partner molecule. The 
mechanism underlying this synergy is presently not well understood. 
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HMGB1 can drive the pathogenesis of infectious diseases as well as autoimmune and auto-
inflammatory diseases [101-103, 114-116]. Elevated levels of total HMGB1 have been 
demonstrated in the serum, synovial tissue and synovial fluid of patients with RA [117, 
118]. Blocking HMGB1 signaling can attenuate inflammation in experimental arthritis 
models [119-121]. In SLE, systemic HMGB1 levels are increased and correlate well with 
disease activity [122-125] and treatment based on HMGB1 antagonists ameliorates the 
course and outcome in experimental lupus [126]. Recently, studies of HMGB1 in myositis 
have also been reported. Cytoplasmic HMGB1 expression was demonstrated in 
inflammatory cells, endothelial cells and even muscle fibers in muscle tissue of patients 
with myositis, suggesting a possible role of HMGB1 in the pathogenesis of myositis [9, 
10].  
 
2.4. TLR2 and TLR4 
TLR2 and TLR4, two members of the toll-like receptor family, are traditionally considered 
to function as membrane proteins and expressed abundantly on the surface of certain 
peripheral blood leukocytes [127, 128]. They are well described as playing important roles 
in the recognition of pathogen-associated molecular patterns (PAMPs), such as lipopeptides 
and lipopolysaccharide from bacteria [129]. Activation of TLR2/4 by PAMPs initiates 
innate immune responses, triggers intracellular signaling pathways via myeloid 
differentiation primary response protein 88 (MyD88) and leads to the production of 
cytokines and chemokines. They can be considered to represent the first line of host defense 
against pathogens and plays an important role in both innate and adaptive immunity [130, 
131]. 
 
Recently several new discoveries have added to our existing knowledge about these TLRs. 
First, in addition to their expression on the immune cells, they have also been found in non-
immune cells including skeletal muscles where TLR2 and TLR4 were detected at both the 
RNA level with polymerase chain reaction (PCR) and the protein level via western blot 
[132, 133]. Second, TLR2 and TLR4 recognize not only PAMPs but also damage-
associated molecular patterns (DAMPs), one of which is HMGB1 [129]. As mentioned 
above, HMGB1 is a very conserved and ubiquitous protein normally found in nuclei of 
cells. HMGB1 can be released from nuclei and from cells under certain conditions and this 
extranuclear/extracellular HMGB1 can induce tissue damage and inflammation via binding 
to its receptors including TLR2 and TLR4 [134-136].  
 
Based on the these advances in our knowledge we postulated that TLR2/4 signaling not 
only exerts important functions in fighting infections but could also play important roles in 
non-infectious disorders, such as autoimmune disease where they could bind endogenous 
ligands such as HMGB1, triggering inflammation and initiating tissue damage. A recent 
report showed that TLR2 expression on skeletal muscles is correlated with insulin 
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resistance and inhibition of TLR2 improves insulin sensitivity [133], suggesting that TLRs 
can play multiple roles in skeletal muscle pathology.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 15 
 
3. Aims of this thesis   
The overall aim of this thesis was to achieve an increased knowledge of the molecular 
mechanisms in myositis that can help to develop new target therapies in myositis in the 
future. This thesis is based on four studies which describe potential roles of four different 
inflammatory molecules in the disease development of myositis.   
The specific aims were: 
 Paper I: To investigate if IL-1 has a role in the disease mechanisms by targeting IL-
1 by anakinra, an IL-1 receptor antagonist, in a mechanistic study and to identify 
possible predicative biomarkers of this treatment.  
 Paper II: To investigate the potential role of IL-15 in the disease mechanisms of 
myositis by investigating whether IL-15 and its specific receptor IL-15Rα are 
expressed in muscle tissue of patients with myositis, the effects of 
immunosuppressive treatment on their expression, and furthermore, the relation of 
IL-15 to the clinical symptoms. 
 Paper III: To investigate the potential role of HMGB1 in the disease mechanisms, 
in particular on muscle fiber function, that is how HMGB1, an alarmin that is 
abnormally expressed in muscle tissue of patients with myositis, may mediate 
muscle dysfunction.  
 Paper IV: To investigate a potential new mechanism for muscle fiber dysfunction 
that is through TLR2, a known defense molecule of the innate immune system by 
investigating its effect on muscle fiber contractility in an animal model and by 
investigating its expression in patients with myositis in relation to clinical 
symptoms.   
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4. Patients 
All the patients who participated in our studies were recruited from the rheumatology unit 
at Karolinska University Hospital, Sweden. All studies were approved by the Regional 
Ethical Review Board in Stockholm and all patients and control individuals gave their 
written informed consent to participate in the study. Patients are being subject to 
standardized follow up including assessment of disease activity and muscle performance.   
 
4.1. Patients in Paper I 
Fifteen patients (8 females and 7males; median age=58 years, range 45-77; median disease 
duration=7 years, range 10 months-19 years) with refractory myositis were included in the 
study. All patients had previously been treated with high-dose prednisolone in combination 
with azathioprine (AZA) or methotrexate (MTX). Six patients had definitive PM and four 
had definitive DM according to Bohan and Peter’s criteria [12, 13] five patients had IBM 
according to Grigg’s criteria [14].  
 
All patients were given self-administered anakinra subcutaneously with a daily dosage of 
100 mg for 12 months. Allowed concomitant treatment included glucocorticoids, AZA, 
MTX or anti-malarial drugs in stable doses during the trial. A positive response was defined 
according to the suggestion of IMACS as ≥20% improvement in three or more of the six 
core set parameters of disease activity and no more than two worsening ≥25% which could 
not include manual muscle test (MMT)-8. Worsening was defined by ≥30% reduction in 
any three of the core set parameters. Improvement of functional index (FI) was defined as 
≥20% increase in FI whereas worsening was defined as ≥20% reduction in FI [79, 137-
139].  
 
We investigated blood samples by ELISA and muscle biopsies by immunohistochemistry 
from these patients before and after treatment in order to find out some possible predictive 
response markers and to get information on whether IL-1 could have a role in the 
pathogenesis of myositis.  
 
4.2. Patients in Paper II 
A cohort of seventeen patients (12 women and 5 men; median age 60 years, range 41-88) 
with PM (n=9) or DM (n=8) according to the Bohan and Peter criteria were included in this 
study [12, 13]. All patients were recently diagnosed and muscle biopsies were taken at the 
first assessment for the study. They were treated with high initial doses of glucocorticoids, 
slowly tapered over the first year. Additional agents were administered according to the 
treating physician’s decision which included MTX, AZA, or cyclophosphamide. The 
second biopsy was obtained after average 8 months’ immunosuppressive treatment (range 4 
-16 months). Clinical outcome was measured by FI, MMT-8 and serum creatine 
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phosphokinase (s-CK). Seven healthy individuals were also included in this study as 
controls (5 women and 2 men; median age 57 years, range 26-78, one patient’s age 
information is missed).   
 
Muscle biopsies from these seventeen patients before and after 8 months’ conventional 
immunosuppressive treatment and seven healthy individuals were investigated by 
immunohistochemistry using antibodies against IL-15 and IL-15Rα. Quantification was 
performed by computerized image analysis. Cellular localization of IL-15 was determined 
by double immunofluorescence.  
 
4.3. Patients in Paper III 
Fourteen patients (8 females and 6 males, median age 46 years, range 26-61) with short 
duration of muscle weakness (median 4 months, range 1-9) were included in this study. 
Muscle biopsies used in this study were selected from patients in the early stages of disease, 
where there were no obvious signs of cellular infiltrates in muscle tissue. The myositis 
diagnosis was based upon cumulative clinical and laboratory findings according to Bohan 
and Peter criteria [12, 13]. A later muscle biopsy confirmed the diagnosis (PM=8; DM=6) 
by presence of inflammation and/or signs of muscle fibre damage. Clinical outcome was 
measured by the FI and serum s-CK. Five healthy individuals (4 females and 1 male, 
median 63 years, range 50-78) without any overt clinical or histopathological signs of 
muscle disease were also included in our study as control.  
 
Muscle biopsies from the patients and healthy individuals were investigated by 
immunohistochemistry using antibodies against TLR4 and MHC-class I. Quantification 
was performed by computerized image analysis.  
 
4.4. Patients in Paper IV  
Six patients diagnosed with polymyositis or dermatomyositis [12, 13] with established 
disease and persisting muscle weakness despite conventional immunosuppressive treatment 
(5 women and 1 men; median age = 69.5 years, range 55-75; median disease duration=47 
months, range 18 months-102 months) were included in this study. They were selected for 
having few inflammatory cell infiltrates in their muscle biopsies. Muscle biopsy samples 
from six healthy, age-matched controls (4 women and 2 men, median age 68.5 years, range 
42-77) without clinical or histopathological signs of any muscle disease were included as 
controls.  
 
Muscle biopsies from these patients and healthy individual controls were investigated by 
immunohistochemistry using antibodies against TLR2.  
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5. Methods 
5.1. Measurement of muscle dysfunction in patients with myositis 
Weakness and fatigue are terms that are often used as if they mean the same thing, but in 
fact they describe two different perceptions. It is important to know exactly what is meant 
when the patients say “feel weak” or “feel fatigued” because it can help the doctor narrow 
down the possible causes of the symptoms.  
 
Muscle weakness is a lack of physical or muscle strength and the feeling that extra effort is 
required to move your arms, legs, or other muscles. If muscle weakness is the result of pain, 
the person may be reluctant to use the muscles as it will hurt. General weakness often 
occurs after you have done too much activity, such as by taking an extra-long cycling or 
hiking trip. MMT is regarded as a reflection of the muscle strength of patients. One 
suggested version of MMT to be used in myositis is the MMT that measures strength in 
eight muscle groups (MMT-8) with a maximum score of 80. Detailed information was 
described in a previous publication [140].  
 
Muscle fatigue is defined as the point when a muscle fails to maintain the required or 
expected force to perform a given activity. Thus, fatigue is not the total exhaustion or a 
complete inability to exert force, but rather more a subtle phenomenon where impaired 
muscle function is demonstrated. Although the presence or development of fatigue is a 
hindrance to physical activity, it may serve as a protective function against muscle damage. 
Myositis functional index (FI) is regarded as a fine measurement for muscle fatigue. It 
measures the number of repetitions performed in defined muscle groups on both sides of 
the body. The individual’s total score is presented as the percentage of the maximal score 
64 [141] .  
 
5.2. Skeletal muscle biopsies from myositis patients  
Muscle biopsy is a very important tool for diagnosis of myopathies. Identification of 
histopathological changes in the muscle tissues obtained from the patients plays an essential 
role in the diagnosis when myositis is suspected, and helps to exclude other myopathies. 
Therefore, a simple and easily used muscle biopsy technique is important, one such being 
the percutaneous conchotome muscle biopsy technique [142] that has been used in Sweden 
both for diagnostic and research purposes. This technique gives a good-sized muscle tissue 
sample that allows for diagnostic evaluation in myositis patients and is also sufficient for 
additional research purposes, such as immunohistochemistry, western blot or gene 
expression detection. It is a simple procedure, easy to perform by the clinician. For the 
patients it is also safe with a low complication rate and minimum discomfort. The method 
serves as a diagnostic tool and by performing repeated biopsies one can assess the effect of 
a given therapy on molecular expression in muscle tissue and correlate this finding with 
clinical outcome measures.  
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5.3. Skeletal muscle sample cryopreservation and cryosection 
Proper freezing and storing of muscle biopsies is very important as it has been found that 
lots of damage and freezing artifacts can be produced when the muscle samples are not 
frozen properly. Reliable immunohistochemistry staining becomes very difficult because 
lots of unspecific staining can be found and the muscle morphology is not good enough for 
evaluation. To avoid these problems and to have good muscle samples for 
immunohistochemistry study, we used the following method to freeze and store our 
samples and to prepare the sections for the staining.   
 
Once we get the muscle tissues, they are put on a physiologically buffer (0.9% saline) 
presoaked cloth for 15 minutes sitting on watery ice. Then the muscle tissue was put into 
isopentane which has been prechilled by liquid nitrogen. Notice directly placing the 
muscles into liquid nitrogen disrupts muscle morphology because of non-uniform freezing 
and should be avoided if you want to perform immunohistochemistry staining. After about 
one minute in the isopentane, the samples were moved directly into a tube on dry ice 
(around -70 ºC). Before putting these samples into -80 ºC freezer for long-term storage, 
some small pieces of watery ice were added to the tubes in order to prevent the samples 
from freeze drying in the future. Repeated freezing and thawing of samples should be 
avoided as it can damage the morphology.  
 
When making cryostat sections from the biopsies, the tissues were kept on dry ice. The 
tissues were mounted on OCT medium and then sectioned. After the sections were 
obtained, they were dried at room temperature for 30 min. The slides were then fixed 
according to characteristics of the antigens to be investigated. Generally, for cell surface 
antigens, acetone fixation was used. Slides were placed in 50% cold acetone for 30 seconds, 
and then 3 minutes in 100% cold acetone. For intracellular antigen detection, slides were 
placed in 2% formaldehyde +4 ºC in darkness, washed twice in cold PBS, and then the 
slides dried at room temperature and were stored at -80 ºC or were used for staining.    
 
5.4. Immunohistochemistry and immunofluorescence  
Immunohistochemical staining is a good technique to demonstrate molecules on muscle 
tissues at protein level.  In our lab, by usage of formaldehyde or acetone fixation we can 
detect intracellular or cell surface markers respectively. We use saponin as a permeabilizing 
detergent when detecting intracellular markers. 1% H2O2 blockade is always performed 
before application of primary antibody. 1% normal serum from the same species as the 
secondary antibody comes from is recommended before or after primary antibody 
application. Routinely, after the secondary antibody incubation, avidin-biotin-peroxidase 
complex (ABC elite, PK-6100, Vector) is applied for 45 minutes and then reactions are 
developed using a peroxidase substrate kit (SK-4100, Vector) containing 3, 3´-
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diaminobenzidine (DAB).  We use Mayer´s hematoxylin counterstaining to show the nuclei 
of the cells. Slides were mounted using glycerol at the end for observation under a 
microscope.  
 
To obtain a nice and reliable staining primary antibody should be carefully chosen and they 
should be titrated on recommended positive tissues/cells in order to know the good 
concentration and suitable protocol for the staining in muscle tissue. If the background is a 
problem, adding a step of avdin/biotin blockade or enhancing the serum concentration in 
the serum blockade step could be considered. Including a negative control with isotype 
staining and a positive control is necessary and helpful.    
 
Immunofluorescence is used in some of our studies in order to distinguish staining to 
different cellular structures. The staining procedure is similar with immunohistochemistry. 
The important issue is that the two primary antibodies should come from different species. 
And all the steps should be performed in the dark as much as possible after fluorophore 
application.       
 
In our lab, stained tissue sections were examined using a Polyvar II microscope and a 
digital Leica camera 300F. The expression of positive markers was quantified on the whole 
tissue sections by computer-assisted analysis with a Quantimet 600 image analyzer usually 
by two independent observers who were blinded to the identity of specimens. The average 
scores from the two assessments were used for statistical analysis. Positive staining was 
either calculated as the number of positive cells per mm
2
 tissue area or as the percentage 
positively stained area of total counterstained tissue area (mm
2
). 
  
5.5. Skeletal muscle cell culture  
In order to develop skeletal muscle cell culture, it is necessary to introduce myosatellite 
cells. Myosatellite cells are adjacent to the sarcolemma of a differentiated muscle fiber and 
situated between the basement membrane (endomysium) and sarcolemma (cell membrane) 
of individual muscle fibers. Satellite cells are able to differentiate and fuse and augment 
existing muscle fibers and also to form new fibers. They are involved in the normal growth 
of muscle and in muscle regeneration following injury or disease. In undamaged muscle 
tissue, the majority of myosatellite cells are quiescent which means they neither 
differentiate nor undergo cell division [78, 143, 144]. Myosatellite cells express distinctive 
genetic markers. It is known that all myosatellite cells express Pax7 and Pax3. Activated 
satellite cells are known to express myogenic transcription factors, such as Myf5 and 
MyoD. They also express muscle specific filament proteins such as desmin [145-147].  
Figure 1 shows the Pax7 staining of satellite cells in the muscle tissue of a patient with 
myositis.   
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It is extremely complicated to perform interventions on human skeletal muscle fibers in 
vivo. In vitro experiments on human cultured muscle cells can be used to address some 
research questions. These muscles cells can be differentiated from satellite cells in muscle 
tissue from patients or healthy individuals. Then investigations can be done in vitro based 
on these cultured cells. Although it cannot completely represent the situation in vivo but so 
far it is the best way to examine mechanisms at present.  
 
The muscle cell culture procedure can be divided into two different stages based on the 
stage of muscle development and are referred to myoblast and myotubes. Myoblast is a 
muscle precursor exhibiting reasonably similar metabolic characteristics to adult skeletal 
muscle; but it does not physically resemble a differentiated muscle fiber or myotube. 
Myoblasts can differentiate into myotube (Figure 2), usually by starving them by reducing 
serum in the culture medium. The distinct morphological difference between myoblasts and 
myotube is that myoblast is mononuclear cell while myotube is multinucleated. As 
myoblasts fuse, they undergo a dramatic switch of phenotype that depends on the 
coordinated activation of a large number of muscle-specific genes and increased expression 
of skeletal muscle specific proteins such as myosin and MyoD. In addition to cultivate and 
differentiate muscle cells from human muscle tissue there are several muscle cell lines 
available on the market; the most often used are C2C12 which is from mouse skeletal 
muscle, and L6 derived from rat skeletal muscle. 
 
Figure 1. Pax7 staining of satellite cells in the muscle tissue of a patient with myositis. Brown color shows 
Pax7 positive satellite cells. Blue color demonstrates nuclei of muscle fibers and infiltrating cells. 
Magnification 20x.  
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5.6. Enzymatic muscle single fiber dissociation and free myoplasmic Ca
2+
 
concentration ([Ca
2+
]i ) measurement 
Enzymatically dissociated flexor digitorum brevis (FDB) muscle fibers were used in some 
of our studies to detect the effects of TLR ligands on muscles. The protocol was described 
previously by Liu and co-workers [148]. Briefly, the whole FDB muscles were removed 
from the toe of the mice. The tendons, connective tissue and blood vessels around FDB 
muscles were cleaned carefully under a microscope using a pair of forceps and micro-iris 
scissors. Clean FDB muscles were incubated for 2-3 hours at 37 ºC in 0.3% collagenase 
type I in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal 
bovine serum. Then muscles were transferred to fresh DMEM and gently triturated about 
30 times to dissociate single muscle fibers. 300 µl of the resultant muscle fiber suspension 
was then transferred to laminin coated glass-bottom Petri dishes and allowed to attach for 
up to 15 minutes before 2.7 ml DMEM supplemented with antibiotic, antimycotic solution 
(1 μL/ml, Sigma) was added. Fibers were incubated overnight at 37 ºC for use on the 
following day.  
 
[Ca
2+
]i was measured in the dissociated fibers during a fatiguing protocol consisting of 300 
intermittent tetanic contractions (70 Hz, 350 ms duration, 2 s intervals) using the 
fluorescent Ca
2+
 indicator indo-1. Briefly, muscle fibers attached to laminin-coated glass-
bottom dishes were incubated with indo-1 AM (4 µM) for 20 min, followed by a 20 min 
wash. Change in indo-1 fluorescence was measured with a PTI system consisting of a 
Xenon lamp, a monochromator and two photomultiplier tubes. Excitation light was 360 ± 5 
nm and the emitted fluorescence was collected after passing through a dichroic mirror at 
Figure 2. An immunofluorescence staining picture showing the myotube forming process where two 
myoblasts are trying to fuse with each other (arrow). Desmin demonstrate the myoblasts (red color), blue 
color indicates the nuclei of cells. Magnification 40x.  
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405 ± 5 nm and 495 ± 5 nm. The ratio of the light emitted at 405 nm and 495 nm was 
translated to [Ca
2+
]i as described previously [149, 150]. 
 
5.7. Mechanical muscle single fiber dissection, force and [Ca2+]i measurement 
Mechanically dissected single fibers were used to measure muscle force and [Ca
2+
]i as 
described earlier [151-153]. Briefly, single fibers were isolated under a dark-field 
illumination microscope using a pair of forceps and micro-iris scissors. The FDB muscles 
were split into three bundles after which each bundle was trimmed down to two or three 
fibers. One fiber was selected and the rest were killed by cutting through the sarcolemma, 
leaving only the selected fiber alive. The fiber’s ability to contract was tested by focal 
electrical stimulation. After isolation of a single fiber, the tendons were gripped by 
platinum-foil micro-clips and the preparation was transferred to the perfusion channel of an 
experimental chamber, placed on the stage of an inverted microscope. The bottom of the 
chamber consisted of a thin glass cover slip and fibers were mounted as close as possible to 
this. The fiber was flanked by platinum electrodes which were used for stimulation.  
 
Force from mechanically dissected fibers was measured using an Akers 801 force 
transducer vertically mounted in the experimental chamber. The force transducer was 
provided with a glass tube extension with a fine platinum hook at the end. On the other end 
of the chamber, there was an adjustable hook. The tendon clips were attached to the two 
hooks, suspending the fiber horizontally. The fiber was stretched to the optimal length (the 
length giving the maximal tetanic force) and the diameter of the fiber at this length was 
measured in order to calculate the developed force per cross-sectional area.  
 
The [Ca
2+
]i measurements in these dissected fibers are basically same as in the 
enzymatically dissociated fibers as described above. The main difference was that the 
dissected fibers were loaded with indo-1 by pressure-injection into the fibers. Subsequent 
procedures to measure [Ca2+] were the same as described earlier for the dissected fibers.    
 
5.8. Western blot  
For western blot, the muscles were homogenized with a motor-driven ground glass 
homogenizer in ice cold homogenization buffer (20 µl per mg wet weight; pH 7.4) The 
homogenate was centrifuged at 700g for 5 min at +4°C. The supernatant was transferred to 
a new tube and the protein concentration was determined using the Bradford assay. Lysates 
were diluted 1:1in Laemmli buffer, left overnight at +4 °C and then heated for 10 min at + 
70 °C. Subsequently, 10 µg of protein was loaded and run on a NuPAGE Novex 4-12% 
precast Bis-Tris gel. Proteins were then transferred to polyvinylidine fluoride membranes. 
Membranes were blocked for 1 hour at room temperature in blocking buffer, followed by 
incubation overnight at + 4 °C with primary antibodies. Membranes were washed in Tris-
buffered saline-Tween 20 (TBS-T) and incubated for 1 hour at room temperature with 
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secondary antibody. Membranes were then washed in TBS-T and immunoreactive bands 
were visualized by an infrared fluorescence microscopy.  
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6. Results and discussion  
In the following sections the main results of Paper I-IV are summarized and together with 
unpublished data discussed in the context of recent findings and literature.  
 
6.1. Paper I: Anakinra treatment in patients with refractory inflammatory myopathies 
and possible predictive response biomarkers: a mechanistic study with 12 months 
follow-up.  
Overexpression of IL-1α and IL-1β was demonstrated in muscle tissue of patients with 
myositis [50, 51], which indicate a role of IL-1 in the pathogenesis of myositis.  Moreover, 
some benefinial effects of IL-1 blockade were reported in a case study of one myositis 
patient with anti-Jo-1 autoantibodies [52], but whether IL-1 has a role in the pathogenesis 
was not clarified.  Therefore, we initiated a mechanistic, open label study with anakinra in 
fifteen patients with refractory myositis. 
 
We found that seven out of fifteen patients with refractory myositis responded to anakinra 
according to the IMACS definition of improvement. Furthermore, we showed that 
clinically, patients with extra-muscular symptoms responded better to anakinra than those 
without; immunologically, CD163+ macrophages, IL-1α expression in muscles, and CD4+ 
activated memory T cells in blood might be negative markers for response to anakinra 
treatment. Due to the limited number of the patients in this study these results should be 
concluded carefully. Finally, we demonstrated that neutralizing IL-1 reduced T cell 
differentiation into Th17. Immunohistochemical analyses did not show any differences in 
inflammatory cells or molecules including T cells and IL-1 in the muscles before and after 
treatment.   
 
In conclusion, anakinra treatment could be beneficial in a subgroup of patients with 
myositis, but biomarkers to predict response need further investigation. The lack of effect 
on IL-1 expression in muscles questions the role of IL-1 in the mechanisms that cause 
muscle weakness in these patients. Our data also suggest that a large scale placebo 
controlled trial with anakinra in myositis patients is needed. Such an investigation may also 
be able to shed more light on the molecular mechanisms of anakinra and on the role of IL-1 
in disease mechanisms in myositis.  
 
6.2. Paper II: Effects of immunosuppressive treatment on IL-15 and IL-15Rα 
expression in muscle tissue of patients with polymyositis and dermatomyositis.  
In our anakinra study, we found that T cells persist in muscle tissue after treatment, even in 
the patients who have good response to anakinra. Our earlier observation also showed that 
while the number of macrophages are decreased or even disappeared after glucocorticoid 
treatment, T cells in muscle tissue are usually maintained [53, 54]. As the most important T 
cell-growth factor, IL-2 is rarely found in muscle tissue of patients with myositis, it is 
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possible that other cytokine (s) may have IL-2-like functions stimulating T cell proliferation 
and differentiation [55-59]. In this context, we started our IL-15 investigation. The study was 
based on muscle biopsies before and after immunosuppressive treatment in seventeen 
recently diagnosed patients.    
 
We found that IL-15 was expressed in macrophages in muscle tissue of all patients with 
polymyositis or dermatomyositis and IL-15Rα was expressed in inflammatory cells in 15 
patients, on capillaries of 11 patients and large vessels of 13 patients. Only occasional 
mononuclear cells were found to be positive for IL-15 and IL-15Rα in healthy controls. An 
inverse correlation was found between baseline IL-15 expression in muscle tissue of 
patients and changes of the muscle performance ∆FI (r=-0.81, P=0.0002). There was a 
reduction in the number of IL-15 and IL-15Rα positive cells after a median of eight months 
with conventional immunosuppressive treatment, but nearly half of the patients (8 out of 
17) still had a higher number of IL-15 expressing cells in muscle tissue after treatment 
compared to healthy individuals and this group of patients had less improvement in muscle 
performance test compared to those patients with a low number of IL-15 expressing cells in 
the muscles after treatment, both after eight months treatment and at a five-years follow up.  
 
A correlation was found between baseline IL-15 expression and CD3+ T cells in muscle 
tissue of patients (r=0.6, p=0.02). And the change of IL-15 expression after treatment 
correlated with change of CD3+T cells (r=0.6, p=0.01). Immunofluorescence demonstrated 
a close localization between IL-15 positive cells and CD3+T cells in muscle tissue of 
patients. Thus, the positive correlation between IL-15 and CD3+T cells, and their close 
localization might support our hypothesis that IL-15 might help to sustain T cell activation 
and homeostasis in muscle tissue of patients with myositis [65, 154, 155].  
 
In conclusion, we demonstrated that IL-15 and IL-15Rα are expressed in muscle tissue of 
patients with PM or DM. They might play a role in sustaining T cell proliferation and 
homeostasis in muscles. Moreover, a correlation was found between IL-15 expression and 
clinical outcome. Therefore, targeting IL-15 might be a novel potential therapeutic target in 
PM and DM, at least in that subgroup of patients with high IL-15 expression in muscle 
tissue after conventional immunosuppressive treatment.  
 
6.3. Paper III: TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis.  
Next, we focused on the question on which other mechanisms could contribute to muscle 
weakness than T cell mediated myocytotoxicity. To address this question we selected to 
investigate muscle biopsies from a group of patients with muscle weakness and muscle 
fatigue but whose muscle biopsies had no obvious inflammatory infiltrates. Earlier we had 
observed that myoplasmic localization of the inflammatory mediator HMGB1 is often 
found in combination with MHC-class I in muscle fibers from patients with myositis even 
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when inflammatory infiltrates were not detectable. Furthermore, exogenous HMGB1 could 
accelerate the development of muscle fatigue and induce MHC-class I expression in adult 
mouse skeletal muscle fibers in vitro [9, 10]. In order to investigate the mechanisms by 
which HMGB1 may worsen muscle fatigue, we set out to investigate which receptors 
HMGB1 acts via in adult skeletal muscle fibers in order to contribute to muscle fatigability 
and MHC-class I expression. We used dissociated single muscle fibers from FDB of WT, 
RAGE knock-out (RAGE-/-) and TLR4 knock-out (TLR4-/-) mice. Immunohistochemistry 
was used to investigate TLR4, MHC-class I and myosin heavy chain expression in muscle 
fibers from fourteen patients with myositis with a short duration of muscle weakness and 
without detectable cellular infiltrates in muscle biopsies.  
 
From the animal study we found that TLR4, but not RAGE, may mediate muscle fiber 
dysfunction via HMGB1. In myositis patients, we demonstrated that TLR4 was expressed 
on muscle fibers. By staining of consecutive sections of muscle biopsies from myositis 
patients for TLR4 and MHC-class I expression we could demonstrate that these two 
molecules were co-localized to the same muscle fibers and that these fibers were fast twitch 
type II fibers. As there was no inflammation or other pathological changes apart from 
cytosolic localization of HMGB1 in the muscle fibers of these patients, we speculate that 
HMGB1 may act via TLR4 to induce expression of MHC-class I. This hypothesis is 
supported by the results from our in vitro study of isolated mouse muscle fibers. 
Furthermore, we also established that as the disease progresses, both MHC-class I and 
TLR4 could be detected in an increasing number of muscle fibers [47] (Figure 3). We also 
detected TLR4 expression in muscle fibers of healthy individuals but HMGB1 and MHC-
class I were absent which suggested again that HMGB1 plays a key role in causing muscle 
dysfunction in patients with myositis.  
 
In conclusion, exposure of differentiated skeletal muscle fibers to HMGB1 resulted in 
greater muscle fatigue and induced MHC-class I expression via a TLR4-dependent 
pathway. HMGB1, TLR4 and MHC-class I co-localization was frequently observed in 
muscle fibers of myositis patients. Therefore, the HMGB1-TLR4 pathway is a potential 
novel target for therapy in myositis patients. This may in particular be interesting in the 
chronic phase, when treatment with conventional therapies has failed.  
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6.4. Paper IV: Loss of TLR2 increases fatigue resistance in mouse skeletal muscles.  
Apart from RAGE, TLRs including TLR2 and TLR4 are also receptors that HMGB1 may 
use to bind and transfer signals. During our exploration in paper III, we found some 
interesting muscle function modifications when TLR2 was knocked out. Therefore we 
decided to further investigate this molecule and its relation to muscle fiber weakness. 
 
TLRs, a group of receptors that bind the peptides from bacteria/virus, are expressed on 
immune cells and contribute to the innate immune response. Recently several studies have 
shown that TLRs can also be expressed on non-immune cells including skeletal muscle 
fibers.  However, the functions of TLRs on these non-immune cells are poorly understood.  
 
Figure 3. Representative pictures of TLR4 immunohistochemistry staining in muscle biopsies from healthy 
individuals, early myositis and chronic myositis patients. Early myositis group consisted of 14 patients (8 
females and 6 males, median age 46 years, range 26-61) with short duration of clinical symptoms (median 4 
months, range 1-9) and without detectable cellular infiltrates in muscle biopsies. Chronic myositis group 
consisted of five patients (3 females and 2 males, median age 66 years, range 53-76) with a long duration of 
clinical symptoms (median 55 months, range 48-72) and cellular infiltrates in their muscle biopsies. Healthy 
individuals (4 females and 1 males, median 63 years, range 50-78) without any clinical or histopathological 
signs of muscle disease were used as controls.  Brown color shows the positive staining. Nuclei stained by 
hematoxylin were shown by blue color. Scale bar 25µm. Magnification x10.  
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When we explored the receptors through which HMGB1 may exert its effects on muscle 
fibers we used knock-out mice for the receptors known to mediate effects of HMGB1, and 
observed that muscle fibers from TLR2 knock-out mice displayed different properties upon 
stimulation compared to fibers from WT and other TLR knock out mice.  The fibers from 
TLR2-/- mice demonstrated significantly increased fatigue-resistance as shown by the 
number of tetani needed to reduce force to 40% of the initial force when fatigued with 
repeated intermittent tetanic stimulation (Figure 4A). We also observed that tetanic [Ca
2+
]i 
was statistically significantly higher at all stimulation frequencies (p < 0.001) in TLR2-/- 
compared to WT muscle (Figure 4B), while tetanic force was similar in TLR2-/- and WT 
muscles (Figure 4C). A similar improved muscle fatigue-resistance was observed in TLR9-
/- mice and a trend in TLR3-/- mice, but their tetanic [Ca
2+
]i was not changed.  Therefore, 
we focused our further investigations on the roles of TLR2 in skeletal muscle function. 
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We next stimulated the muscle fibers from WT mice with known TLR2 ligands, HMGB1 
and Pam3CSK, and we found that activation of TLR2 signals with either ligand could 
accelerate muscle fatigability. Western blots were also performed to investigate the muscle 
intrinsic proteins and mitochondrial enzyme activities in muscles from WT and TLR2-/- 
mice. We found that enhanced fatigue-resistance in TLR2-/- mice could relate to the 
increased anti-oxidant ability as superoxide dismutase (SOD) 1 and SOD2 were increased 
dramatically in these knock out mice. Moreover, the higher tetanic calcium release from 
TLR2-/- mice could be explained by an increased amount of calcium-binding proteins in 
the muscles as more calsequestrin and sarcalumenin were found in these mice. Next we 
investigated whether TLR2 is expressed in skeletal muscle biopsies from patients with 
myositis. Indeed, we found that TLR2 together with one of its endogenous ligand, HMGB1, 
was expressed in muscle fibers of patients with myositis.  
 
Together with the animal study, we suggest that the TLR2 signal could play a role in 
causing muscle problems in patients with myositis and modifying this signal may be a way 
to improve muscle function of these patients in the future.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Skeletal muscle fibers from TLR2-/- mice showed increased fatigue-resistance and more 
tetanic [Ca2+]i. (A) Number of tetani needed to reduce force to 40% force is greater in TLR2 than in WT 
dissected single FDB muscle fibres. A similar improved muscle fatigue-resistance was also observed in 
TLR9-/- mice and a trend in TLR3-/- mice, but not in TLR4-/- mice.  (B) Tetanic [Ca2+]i was statistically 
significantly higher in TLR2-/- compared to WT muscle but this property was not observed in TLR4-/- 
,TLR3-/- and TLR9-/- mice.  (C) Tetanic force at all stimulation frequencies was not different between 
TLR2-/-, TLR4-/-, TLR3-/, TLR9-/- and WT muscles.  
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7. Future perspectives 
IL-1: Whether IL-1 has a role in the pathogenesis in myositis is still unclear. Blocking IL-1 
by anakinra had beneficial effects on clinical outcome measure in some patients with 
refractory myositis. An indication of a biological effect was suggested by the effects on 
peripheral blood cells but no effect was seen on the inflammation in muscle tissue. From 
our mechanistic study with a limited number of patients we could not identify predictive 
markers for responders in whom IL-1 would be more likely to have a role in the molecular 
pathways of disease. This would require a larger controlled trial. Such a trial is ongoing in 
collaboration with a pharmaceutical company. 
 
IL-15: In our first study we investigated IL-15 and its specific receptor expression in 
patients with PM and DM. Now I have completed staining on a few patients with IBM and 
could demonstrate that IL-15 is also expressed in muscle tissue of this subgroup of patients 
(Figure 5). In the future, we should confirm their expression in IBM in a larger cohort.  
 
 
 
In addition, T cell infiltration in muscle tissues of myositis patients is an important 
histological feature of these diseases, especially in PM and IBM patients. We have 
previously shown that T cell infiltrates in muscle tissue of PM and DM patients are 
Figure 5. IL-15 was expressed in CD163+ macrophages in muscle tissue of patients with IBM. (A) 
Immunofluorescence staining  showing IL-15 expression in inflammatory cells. Green color indicates 
positive staining. (B) CD163+ macrophages in red by immunofluorescence. (C) Nuclei were shown by 
DAPI. (D) Overlay picture demostrates that IL-15 was expressed by CD163+ macrophages. Magnification 
32x.  
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dominated by a subset of T cells so called CD28
null
 T cells, and these infiltrates often persist 
even after immunosuppressive treatment which indicate  some continuous stimulator for 
these T cells [156]. CD28
null
 T cells were also shown to be expanded in blood of myositis 
patients.  In addition, muscle and blood CD28
null
 T cells shared the same restricted TCR-
Vβ, suggesting that these cells may have a common origin and antigen specificity [157]. 
One important function of IL-15 is to stimulate proliferation of human memory CD8+T 
cells. This has been proven by IL-15-/- mice in which reduced numbers of memory-
phenotype CD8+ T cells were found in the spleen and lymph nodes that were reversible 
upon provision of exogenous IL-15 [57]. Interestingly, a role for common gamma chain 
cytokines in the down-regulation of CD28 expression on CD8+ T cells has been 
demonstrated. As an important member of these cytokines, IL-15 has been shown to play 
an important role in the generation of CD28
null
 CD8+ memory T cells [158]. In our studies 
we have now demonstrated that both IL-15 and CD28
null
 T cells exist in the muscle tissue 
of myositis patients. In the future it might be interesting to determine the role that IL-15 
plays in the generation and proliferation of CD28
null
 cells of either CD4 or CD8 lineage in 
myositis patients. 
 
HMGB1: HMGB1 has from our studies turned out to be a potential candidate to block in 
future studies of patients with myositis. In particular, HMGB1 may have a role in the early 
phase of the disease as a factor triggering the initial local inflammation in the muscle tissue 
having effects on muscle fiber phenotype with e.g. upregulation of MHC class-I and also 
clearly having effects on muscle fiber performance inducing muscle fatigue. At the cellular 
level, the signaling pathways by which HMGB1 impairs muscle performance require 
further investigation. The redox states of HMGB1 in myositis and whether cytokine 
signatures can modify its redox states also need detailed future studies. In addition, one 
interesting demonstration in our immunohistochemistry study is that both HMGB1 and 
TLR4 (also TLR2) can be detected in the cytosol of muscle fibers, which raises the 
possibility that they could bind to each other and mediate muscle dysfunction before they 
are released out of cells. This hypothesis needs to be further investigated. Finally, the 
mechanism (s) that causes HMGB1 to translocate from nuclei to cytosol especially in 
muscle fibers from patients with normal-looking muscle morphology and without 
inflammatory infiltrates is still unclear and should be investigated. In this context the role of 
hypoxia is interesting. Hypoxia has been demonstrated to induce HMGB1 release from 
hepatocytes [159], in synovitis [160] and in ischemia-reperfusion injuries [161, 162]. 
Hypoxia has been implicated to occur in myositis. Capillaries are lost in muscles of patients 
with PM and DM [163, 164]. VEGF is highly expressed in muscle tissues [165]. 
Furthermore, hypoxia-inducible 1-α, a sensitive marker of hypoxia, is overexpressed in 
muscle tissues of patients with PM and DM compared with healthy individuals [166]. In 
addition, hypoxia can also prevent cysteines from being irreversibly oxidized and therefore 
potentially provides a supportive environment for HMGB1 to stay in the dangerous redox 
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state enabling its binding to TLR4 [167]. Muscle is an organ that is particularly dependent 
on oxygen for its metabolism and thus sensitive to hypoxia, whether hypoxia in muscle 
tissue could be a trigger of inflammation that in some individuals lead to a chronic 
inflammation still needs to be investigated.  
 
TLRs: We believe that our current study just reveals a tiny tip of the iceberg about the roles 
of TLRs in the skeletal muscle function. It will be very interesting to determine other TLRs 
expression and function in the muscle fibers of patients. For example, TLR7, TLR8 and 
TLR9 are related to the type I interferon signaling which has been shown to be expressed in 
muscle tissue and peripheral blood of subsets of myositis patients especially in 
dermatomyositis patients and in patients with anti-Jo-1 antibodies. Therefore, it would be 
interesting to investigate the expression of these TLRs and to see how muscle function will 
be influenced by modifying their expression in skeletal muscle using mouse models. There 
are hints that TLRs expression is altered by the health status. It was already shown that 
exercise can reduce TLR2 and TLR4 expression on monocytes in healthy individuals [168, 
169]. Exercise can benefit myositis patients with improved muscle performance but the 
mechanism underlying this effect still needs to be clarified [41, 43, 170-174] . The TLRs 
and how they change after exercise in myositis patients would be interesting to explore in 
future studies.   
 
Beclin1: In addition to the above inflammatory cytokines/molecules that we investigated, 
during my PhD study I also became very interested in another molecule, Beclin1, which is a 
molecule involved in the upstream autophagy signaling.  
 
A recent study showed that endogenous, cytosolic HMGB1 protein can induce autophagy 
by binding Beclin1 (an upstream protein initiating autophagy) and help the cell to survive 
under certain conditions [175]. This raised our interest because we have found that HMGB1 
is abundantly expressed in the cytosol of inflammatory cells in muscle tissue of patients 
with myositis [10]. T cells express genes encoding autophagy which seems to be essential 
for proliferation of T cells after receptor activation [176]. Thus, there is a possibility that 
HMGB1 may also contribute to the T cell survival and proliferation in myositis by binding 
Beclin1 and inducing autophagy and thereby promote the chronic inflammation in muscle 
tissue. Therefore, we investigated whether Beclin1 is expressed in the muscle tissue of 
patients with myositis. 
 
We found that both Beclin1 and HMGB1 were detected in mononuclear infiltrating cells in 
muscle tissue of nine investigated patients with myositis, and their expression co-localized 
to the infiltrating T cells in muscles as demonstrated by both staining of consecutive 
sections (Figure 7A-C) and double fluorescence staining of muscle tissue (Figure 7D-F). 
Therefore, we suggest that autophagy of T cells could be initiated by HMGB1-Beclin1 
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binding in muscle tissue of patients with myositis and this pathway may contribute to T cell 
survival in the muscles. This project is now under investigation.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Beclin1 and HMGB1 were expressed in muscle tissue of patients with myositis and co-
localized to infiltrating T cells. (A) A representative section of Beclin1 expression in the infiltrating 
cells in the muscles. Brown color indicates positive staining. Blue color:  nuclei of the cells. Note that 
bluish nuclei can be seen clearly in the infiltrating cells which indicate that Beclin1 was mainly 
localized to the cytosol. (B) A consecutive section stained with HMGB1 showed that HMGB1 was 
expressed in the infiltrating cells. Note that bluish nuclei are not easily visible anymore which indicates 
that HMGB1 localized to both the nuclei and cytosol of infiltrating cells. (C) A consecutive section 
stained by CD3 marker showing that T cells dominated in the infiltrating cells. (D) Immunofluorescence 
staining showing CD3+ T cells in the infiltrates. Red color indicates positive staining. (E) 
Immunofluorescence staining indicated HMGB1 expression in the infiltrating cells. Green color 
indicates positive staining. (C)  Overlay picture of D and E showing that HMGB1 is expressed in the T 
cells; Magnification 20x in A-C and 10x in D-E.  
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8. Conclusions 
Myositis is a group of heterogeneous diseases primarily with muscle weakness and muscle 
fatigue as the most common and dominant symptoms. High-dosage of long-term 
glucocorticoids is the most widely used treatment so far, but efficacy is limited and side 
effects are worrying. Therefore, development of new therapies is strongly needed. 
Biological therapies, e.g. TNF blockade, have been encouraging in RA. However, the 
resistance to these therapies in myositis emphasizes the need for fundamental molecular 
knowledge to help develop new treatment options for patients with myositis.  
 
In my thesis, we investigated the expression of four molecules in muscle tissue and their 
potential roles in the disease development of myositis. In brief, we found that: (I) IL-1 may 
have a role in the disease mechanisms in a subgroup of patients but this needs to be further 
explored. (II) IL-15 may be a potential new target for treatment as IL-15 and IL-15Rα were 
expressed in muscle tissue of patients with myositis even after immunosuppressive 
treatment and patients with higher levels of IL-15 had a more severe muscle dysfunction 
both from a short and long term observation. (III) HMGB1 and TLR4 are present in muscle 
tissue of patients with myositis who have muscle weakness and in vitro experiments 
showed that rHMGB1 can accelerate muscle fatigue and induce MHC-class I via TLR4. 
Therefore the HMGB1-TLR4 pathway may be of interest for future targeting therapies in 
these patients. (IV) Finally, TLR2, a receptor for pathogens in immune cells may have a 
totally different role in muscle fibers and may be involved in the mechanism of muscle 
fatigue; the explanation for this is unclear but raises the possibility of a new pathway to 
target in future studies in patients with muscle weakness and fatigue.  
 
In summary, the investigations of the studies in my thesis suggest that different molecules 
may play a role in the pathogenesis of myositis. Different molecules can contribute to the 
disease development at different stages and through different mechanisms. We did not find 
one key molecule in myositis at least not during my explorative journey, and it is hard to 
believe in its existence due to the complexity and heterogeneity of myositis. A possible way 
to continue the molecular studies in myositis in the future might be in subgroups with 
homogenous clinical phenotypes and should involve a combined investigation of genes and 
environment as well as in combination with animal models. 
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